Bicara Therapeutics (NASDAQ: BCAX) net income
Bicara Therapeutics reported a net loss of $138.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $68.0m. Earnings per share were −$2.52.
Bicara Therapeutics's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$138.0m | — | — | −$2.52 |
| 2024 | −$68.0m | — | — | −$4.05 |
| 2023 | −$52.0m | — | — | −$89.61 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Bicara Therapeutics net income compared with its sector
By net income for its latest fiscal year, Bicara Therapeutics ranks 369th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 367th | NovoCure | −$136.2m | — |
| 368th | Zentalis Pharmaceuticals | −$137.1m | — |
| 369th | Bicara Therapeutics | −$138.0m | — |
| 370th | Inhibrx Biosciences | −$140.1m | −10,773.5% |
| 371st | 4D Molecular Therapeutics | −$140.1m | −164.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Bicara Therapeutics
- How much did Bicara Therapeutics earn in fiscal 2025?
- Bicara Therapeutics reported a net loss of $138.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $68.0m.
- What are the earnings per share of Bicara Therapeutics?
- They were −$2.52 in fiscal 2025, compared with −$4.05 in fiscal 2024.
- Where does Bicara Therapeutics rank in its sector by net income?
- It ranks 369th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Bicara Therapeutics come from?
- From the annual report (Form 10-K) that Bicara Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Bicara Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Bicara Therapeutics: the Bicara Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.